Janux Therapeutics, Inc.

NasdaqGM:JANX 株式レポート

時価総額:US$2.6b

Janux Therapeutics マネジメント

マネジメント 基準チェック /44

Janux Therapeuticsの CEO はDavid Campbellで、 Jun2017年に任命され、 の在任期間は 7.42年です。 の年間総報酬は$ 4.19Mで、 14.9%給与と85.1%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.54%を直接所有しており、その価値は$ 13.77M 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と3.7年です。

主要情報

David Campbell

最高経営責任者

US$4.2m

報酬総額

CEO給与比率14.9%
CEO在任期間7.4yrs
CEOの所有権0.5%
経営陣の平均在職期間2.3yrs
取締役会の平均在任期間3.7yrs

経営陣の近況

Recent updates

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Oct 01
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Janux Therapeutics: Buoyed By Buyout Speculation

Sep 01

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Jul 01
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 11

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Feb 24
Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Dec 29
Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Nov 04
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

Jul 20
We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 23
A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Feb 09
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Oct 19
We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Aug 09

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Jun 05
We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Feb 19
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Nov 03
Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

CEO報酬分析

Janux Therapeutics の収益と比較して、David Campbell の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$61m

Jun 30 2024n/an/a

-US$44m

Mar 31 2024n/an/a

-US$56m

Dec 31 2023US$4mUS$625k

-US$58m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$67m

Dec 31 2022US$6mUS$550k

-US$63m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$8mUS$459k

-US$33m

Sep 30 2021n/an/a

-US$21m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$812kUS$405k

-US$7m

報酬と市場: Davidの 総報酬 ($USD 4.19M ) は、 US市場 ($USD 6.50M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Davidの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

David Campbell (64 yo)

7.4yrs

在職期間

US$4,193,269

報酬

Dr. David Campbell, Ph D serves as President, Chief Executive Officer and Director of Janux Therapeutics, Inc. since inception in June 2017. He founded Janux in 2017 to develop tumor-specific cancer therap...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
David Campbell
President7.4yrsUS$4.19m0.54%
$ 13.8m
Charles Winter
Chief Technical Officer1.8yrsUS$1.61m0.098%
$ 2.5m
Byron Robinson
Chief Strategy Officer2.8yrsUS$1.74m0%
$ 0
Matt Whitmire
Vice President of Financeless than a yearデータなしデータなし
Maria Dobek
Principal Accounting Officer & VP of Accountingless than a yearデータなしデータなし
Tommy Diraimondo
Chief Scientific Officerless than a yearデータなし0.19%
$ 4.8m
James Pennington
General Counsel3.3yrsデータなしデータなし
Andy Meyer
Chief Business Officer3.7yrsデータなし0.13%
$ 3.3m

2.3yrs

平均在職期間

47.5yo

平均年齢

経験豊富な経営陣: JANXの経営陣は 経験豊富 であると考えられます ( 2.3年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
David Campbell
President7.4yrsUS$4.19m0.54%
$ 13.8m
Charles Hart
Member of Scientific Advisory Boardno dataデータなしデータなし
Vickie Capps
Independent Director3.7yrsUS$173.01k0.13%
$ 3.3m
Ronald Barrett
Chairperson3.2yrsUS$162.69k0%
$ 0
Mark Davis
Member of Scientific Advisory Boardno dataデータなしデータなし
Alana McNulty
Independent Director3.2yrsUS$166.57k0%
$ 0
Charles Craik
Member of Scientific Advisory Boardno dataデータなしデータなし
Sheila Gujrathi
Director3.7yrsUS$158.01k0.21%
$ 5.5m
Winston Kung
Independent Director2.2yrsUS$164.77k0%
$ 0
Jake Simson
Independent Director3.7yrsUS$172.07k0%
$ 0
Greg Weiss
Member of Scientific Advisory Boardno dataデータなしデータなし
Jennifer Maynard
Member of Scientific Advisory Boardno dataデータなしデータなし

3.7yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: JANXの 取締役会経験豊富 であると考えられます ( 3.7年の平均在任期間)。